帕金森病患者血清表皮生长因子水平变化与认知功能障碍的相关性分析  

Correlation between serum epidermal growth factor level change and cognitive impairment in patients with Parkinson's disease

作　　者：刘慧丽[1] 顾婧 吴春丽[1] Liu Huili;Gu Jing;Wu Chunli(Department of Neurology,Hangzhou Third People's Hospital,Hangzhou 310009,Zhejiang Province,China)

机构地区：[1]杭州市第三人民医院神经内科,杭州310009

出　　处：《中国基层医药》2022年第5期694-697,共4页Chinese Journal of Primary Medicine and Pharmacy

基　　金：浙江省杭州市卫生计生科技计划一般(A类)项目(2017A20)。

摘　　要：目的探讨帕金森病(Parkinson's disease,PD)患者血清表皮生长因子(Epidermal growth factor,EGF)水平变化,分析其与认知功能障碍的相关性。方法选取杭州市第三人民医院2017年7月至2018年6月收治的早期PD患者154例为观察对象,根据认知功能水平将患者分为轻度认知功能障碍(Parkinson's disease mild cognitive impairment,PD-MCI)组(观察组)以及无认知功能障碍组(对照组)。通过蒙特利尔认知评估量表(Montreal cognitive assessment scale,MoCA)进行认知功能评定,通过国际帕金森病与运动障碍协会(MDS)所制定的评定量表第三部分(UPDRS-Ⅲ)量表进行运动功能障碍评定。分别于入组以及2年随访结束时进行上述评估。采用双抗体夹心法测定血EGF水平,将无认知功能障碍患者根据血EGF水平进行四分位分组,比较随访2年后每组患者PD-MCI转化率。结果154例患者中,68例(44.16%)患者为PD-MCI,86例(55.84%)患者无认知功能障碍。观察组患者MoCA评分[(20.01±3.15)分]以及血EGF表达水平[(267.79±63.18)ng/L]均显著低于对照组[(28.21±2.84)分、(491.53±67.38)ng/L](t=8.11、9.03,均P<0.001),UPDRS-Ⅲ评分[(23.47±5.33)分]显著高于对照组[(18.69±4.37)分](t=5.18,P<0.001);第一分位患者中14例(63.64%)患者转化为PD-MCI,而第四分位患者中仅2例(9.52%)转化为PD-MCI;第二、第三及第四分位患者转化率均显著低于第一分位患者(χ^(2)=9.73、14.48、33.47,均P<0.05)。结论PD患者认知功能障碍与血清EGF有密切的相关性,EGF为预测PD患者认知功能障碍的血液学指标,具备显著创新性和科学性。Objective To investigate the change in serum epidermal growth factor(EGF)level in patients with Parkinson's disease(PD)and correlate it with cognitive impairment.Methods A total of 154 patients with early PD who received treatment in Hangzhou Third People's Hospital between July 2017 and June 2018 were included in this study.They were randomly divided into mild cognitive impairment(observation group)and no cognitive impairment(control group)according to the severity of cognitive impairment.Cognitive impairment was graded using Montreal cognitive assessment scale.Motor function was assessed using Unified Parkinson's Disease Rating Scale Part III formulated by International Parkinson and Movement Disorder Society.All these assessments were performed at enrollment and at the end of 2-year follow-up.Serum EGF level was measured by double antibody sandwich enzyme-linked immunosorbent assays.Patients without cognitive impairment were divided into four groups according to quartiles of serum EGF levels.The conversion rate of PD-MCI was calculated at 2 years of follow-up and compared between groups.Results Among 154 patients,68(44.16%)patients developed PD-MCI,and 86(55.84%)patients had no cognitive impairment.Montreal cognitive assessment scale score and serum EGF level in the observation group were(20.01±3.15)points and(267.79±63.18)ng/L,respectively,which were significantly lower than those in the control group[(28.21±2.84)points,(491.53±67.38)ng/L,t=8.11,9.03,both P<0.001].Unified Parkinson's Disease Rating Scale Part III score in the observation group was significantly higher than that in the control group[(23.47±5.33)points vs.(18.69±4.37)points,t=5.18,P<0.001].Among the first quartile group,14(63.64%)patients converted to PD-MCI;while among the fourth quartile group,2(9.52%)patients converted to PD-MCI.The conversion rate of PD-MCI in the second,third and fourth quartile groups was significantly lower than that in the first quartile group(χ^(2)=9.73,14.48,33.47,all P<0.05).Conclusion Cognitive impairment in

关 键 词：帕金森病 表皮生长因子 认知障碍 因素分析 统计学 

分 类 号：R742.5[医药卫生—神经病学与精神病学]